UK becomes first in Europe to approve Eli Lilly’s oral weight-loss and diabetes drug orforglipron

Britain leads Europe by approving Eli Lilly’s orforglipron, the first oral GLP-1 tablet for weight loss and type 2 diabetes, marking a significant step in obesity and diabetes treatment. The UK’s medicines regulator has authorised Eli Lilly’s orforglipron, a once-daily…













